Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In view of these chromosomal aberrations, the CD30+ ALCLs represent a heterogeneous group because 15% to 50% express the NPM/ALK fusion gene.
|
9561912 |
1998 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The diagnosis of ALCL was based on immuno-morphological features and all the cases but 2 were investigated using ALK1 antibody directed to the NPM/ALK protein associated with the 2;5 translocation.
|
9808552 |
1998 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tumor cells in t(2;5)+ lesions also stained immunohistochemically for p80NPM/ALK, whereas no staining for p80NPM/ALK was detected in extranodal ALCL.
|
9598798 |
1998 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In summary, we demonstrate that the inv(2)(p23q35), a variant of the t(2;5)(p23;q35), is a recurrent chromosomal abnormality in ALK-positive ALCL, the further characterization of which should provide new insight into the pathogenesis of these lymphomas.
|
9763551 |
1998 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Case two had a typical anaplastic large cell lymphoma (ALCL) morphology, with a suboptimal BM biopsy, but abnormal circulating cells in the PB showing the presence of the NPM/ALK fusion product demonstrated by RT-PCR.
|
9517514 |
1998 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
During the last year the expression of anaplastic lymphoma kinase clarified presentation and provided clues toward the outcome of anaplastic large cell lymphoma; the breakpoints of t(2;5) were mapped; constitutive activation of anaplastic lymphoma kinase by a chromosomal inversion was described; transformation was shown to be independent of nuclear localization of anaplastic lymphoma kinase; and phospholipase C-gamma was identified as a molecular target for the kinase activity of anaplastic lymphoma kinase.
|
10505771 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, ALK expression was confined to the cytoplasm of the tumor cells in each case, supporting the hypothesis that the observed nuclear localization of NPM-ALK in classical ALCL is not the site of oncogenic activity of the ALK kinase.
|
10381534 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
It is important to separate these from cases of ALK-negative ALCL, which have a poorer prognosis, and cases of primary cutaneous ALCL, which have an excellent prognosis.
|
10725869 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These findings indicate that TFG can provide an alternative to NPM as a fusion partner responsible for activation of the ALK and the pathogenesis of ALCL.
|
10556217 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Routine tissue biopsies from five cases of ALK-positive ALCL were also strongly positive for phosphotyrosine.
|
10398126 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, their prognosis was excellent and indistinguishable from that of classical t(2;5)-positive tumors, but was clearly different from that of ALK-negative anaplastic large-cell lymphomas.
|
10552961 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Primary nodal biopsies of 42 patients with ALCL were investigated for the percentage of activated CTLs (quantified using Q-PRODIT) and the expression of ALK by immunohistochemistry using monoclonal antibodies (MoAbs) directed against T-cell antigen granzyme B (GrB) and ALK, respectively.
|
10194449 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In contrast to normal tissues, the two antibodies against the N-terminal portion of NPM labeled the cytoplasm of neoplastic cells, in four ALK-positive ALCL, reflecting their reactivity with NPM-ALK fusion protein, whereas the antibody to the C-terminal NPM epitope labeled only cell nuclei.
|
9885226 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These cells expressed ALK protein, but, in contrast to t(2;5)-positive ALCL (which show cytoplasmic, nuclear, and nucleolar staining), labeling was restricted to the malignant cell cytoplasm.
|
10216106 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We conclude that immunohistochemical studies, using antibody ALK1. and FISH for ALK gene rearrangement are equally effective for identifying patients with ALCL who have a favorable clinical outcome.
|
10555007 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results show how ALCL cases that express ALK proteins other than NPM-ALK can be detected by sensitive biochemical techniques using routine cryostat sections.
|
10362790 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation.
|
9894470 |
1999 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ALK(-) ALCL occurs in older patients, affecting both genders equally and having an unfavorable prognosis.
|
11090048 |
2000 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, NPM-ALK activates the antiapoptotic PI 3-kinase/Akt pathway, which likely contributes to the molecular pathogenesis of ALCL.(Blood.2000;96:4319-4327)
|
11110708 |
2000 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The wide range of NPM-ALK positivity reported in different series appears to be dependent on the inclusion and selection criteria of the ALCL cases studied.
|
10994999 |
2000 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The lymphoma cells did not show overexpression of the anaplastic lymphoma kinase (ALK) gene, which is found in about 50% of the cases of human ALCL.
|
11045569 |
2000 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results confirmed that mRNA encoding ALK protein was not detectable in any normal or neoplastic hematopoietic tissue tested, except for t(2;5)-positive ALCL.
|
10793082 |
2000 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In a screen for variant ALK gene fusions, we identified two ALCL that were negative for NPM-ALK by reverse transcriptase-polymerase chain reaction, but were positive for cytoplasmic ALK with both polyclonal and monoclonal antibodies to the ALK tyrosine kinase domain, consistent with ALK deregulation by an alteration other than the t(2;5) Case 1 was a T-lineage nodal and cutaneous ALCL in a 52-year-old woman, and Case 2 was a T-lineage nodal ALCL in a 12-year-old girl.
|
10702393 |
2000 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RT-PCR analysis of 5 ALCL tumors that contained the inv(2) revealed identical ATIC-ALK fusion cDNA junctions in all of the cases.
|
10706887 |
2000 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
However, these neoplasms can be distinguished from ALCL by virtue of their B-lineage and lack of anaplastic lymphoma kinase-1 expression.
|
10757332 |
2000 |